CSIMarket
 
Amicus Therapeutics inc   (FOLD)
Other Ticker:  
 
 
Price: $10.7100 $-0.11 -1.017%
Day's High: $10.93 Week Perf: 1.52 %
Day's Low: $ 10.68 30 Day Perf: -10.75 %
Volume (M): 5,091 52 Wk High: $ 14.57
Volume (M$): $ 54,525 52 Wk Avg: $12.20
Open: $10.82 52 Wk Low: $9.70



 Market Capitalization (Millions $) 3,183
 Shares Outstanding (Millions) 297
 Employees 1,246
 Revenues (TTM) (Millions $) 399
 Net Income (TTM) (Millions $) -152
 Cash Flow (TTM) (Millions $) 97
 Capital Exp. (TTM) (Millions $) 7

Amicus Therapeutics Inc
Amicus Therapeutics is an American biopharmaceutical company founded in 2002, based in Cranbury, New Jersey. The company is focused on developing and commercializing new treatments for rare and orphan diseases, including lysosomal storage disorders (LSDs) of genetic origin.

The company's mission is to unlock the potential of genetic medicine to improve the lives of people affected by rare and devastating diseases. They are dedicated to conducting rigorous research to uncover new therapeutic approaches to these diseases, and to bringing safe and effective treatments to market.

Amicus Therapeutics has a diverse portfolio of small molecule and gene therapy drug candidates that are designed to address various LSDs. They currently have three approved products: Galafold, a small molecule medication for the treatment of Fabry disease, which is a genetic disorder that leads to the accumulation of a type of fat in the body called globotriaosylceramide (Gb3); Migalastat, an oral medication that is used in combination with enzyme replacement therapy (ERT) for patients with Fabry disease; and Jivi, a recombinant factor VIII therapy used for the treatment of hemophilia A.

In addition to their approved products, Amicus Therapeutics also has several promising drug candidates in development, such as AT-GAA, a gene therapy for Pompe disease that is currently in Phase 3 clinical trials.

Amicus Therapeutics has a strong commitment to patient advocacy and engagement, working closely with patient organizations and advocacy groups to ensure that the needs and concerns of patients are taken into account in their research and development efforts.

Overall, Amicus Therapeutics is a leading company in the field of rare and orphan diseases, with a strong focus on developing innovative and effective treatments to improve the lives of patients affected by these devastating conditions.


   Company Address: 47 Hulfish Street Princeton 8542 NJ
   Company Phone Number: 662-2000   Stock Exchange / Ticker: NASDAQ FOLD
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Amicus Therapeutics Inc

Amicus Therapeutics Inc Faces a Shortfall of $-0.11 per Share in Fourth Quarter of 2023

Amicus Therapeutics Inc, a major player in the pharmaceutical preparations industry, recently announced its financial results for the fourth quarter of 2023. Despite reporting a net loss of $-0.11 per share, the company's revenue experienced a significant surge of 31.466%, amounting to $115.82 million. This represents a remarkable 21% increase in total revenue compared to the previous year.
When compared to the preceding quarter, where the company generated $102.56 million in revenue and reported a net loss of $-0.07 per share, these figures demonstrate promising growth for Amicus Therapeutics Inc. Furthermore, the company's net shortfall decreased from $-55.865 million to $-33.843 million in the same fiscal fourth quarter, indicating improved financial performance.

Amicus Therapeutics Inc

Amicus Therapeutics Inc Faces Mounting Shortfall, Sending Shockwaves through the Pharmaceutical Industry in 2023 Q3

Amicus Therapeutics Inc, a major pharmaceutical preparations company, recently reported a significant surge in revenue by 25.54% to $102.56 million for the fiscal time-frame ending September 30, 2023. This growth outpaced many of its industry competitors. However, upon further analysis, it is evident that there are several concerning factors that indicate a bearish outlook for the company.
First and foremost, Amicus Therapeutics Inc's deficit has extended to $-0.07 per share, which is an alarming figure for investors. While the company's revenue has grown, the fact that it is still operating at a deficit raises concerns about its financial stability and ability to generate sustainable profits.

Amicus Therapeutics Inc

Amicus Therapeutics Inc Shows Resilience with Strong Overall Performance Despite Recent Share Decrease and Increased Losses

Amicus Therapeutics Inc, a pharmaceutical company, has experienced a slight decrease in its shares over the past five trading days. The shares went down by -0.26%, which brings the year-to-date performance to 13.75%. Despite this decrease, it is worth noting that the shares are only 2% short of the 52-week high, indicating a strong performance overall.
Looking at the company's financial performance, it can be observed that for the April to June 30, 2023 fiscal period, there was a significant increase in losses compared to the same period the previous year. The losses swelled to $-0.15 per share, whereas they were $0.00 per share a year before. However, there was an improvement in earnings per share from the prior quarter, increasing from $-0.18 per share.

Amicus Therapeutics Inc

Amicus Therapeutics Inc sees revenue growth, but widening deficit threatens first quarter of 2023 earnings

Investing in the stock market can be an exciting and rewarding experience. However, it is crucial to approach investment decisions with caution and careful consideration. This is especially true when it comes to investing in individual companies and stocks that are subject to fluctuations in performance, such as Amicus Therapeutics Inc.
According to recent financial reports released by Amicus Therapeutics Inc, the company's shortfall per share has expanded to $-0.18 from $0.00 year on year. This is a significant change in performance and should be of concern to investors looking to invest in the company. While revenue growth has increased by 9.598% to $86.27 million, the overall financial picture is not as positive as this growth might indicate.






 

Amicus Therapeutics Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Amicus Therapeutics Inc does not provide revenue guidance.

Earnings Outlook
Amicus Therapeutics inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com